Matthew R. G. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew R. G. Taylor has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Luisa Mestroni
University of Colorado Anschutz Medical Center
13 shared publications Dobromir Slavov
Adult Medical Genetics Program and Division of Cardiology, University of Colorado Denver, Denver, CO, USA
10 shared publicationsLuisa Mestroni
Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Denver, Aurora, Colorado
8 shared publications- Gianfranco Sinagra
Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, 34149 Trieste, Italy
7 shared publications Andrea Di Lenarda
Cardiovascular Department "Ospedali Riuniti" and Cardiovascular Center, ASS1-Trieste and University of Trieste, Trieste, Italy (G.S., M.M., G.B., A.S., F.B., A.D.L.).
6 shared publicationsSharon L. Graw
Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado
6 shared publications
Latest Publications
- 1 October 2022
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 15 (5) , 356-358
Hidden Risk: Arrhythmogenic Genes in the General Population
The past 2 decades have seen the development of large-scale DNA biobanks associated with phenotypic information of the general population. Examples of these efforts are the UK Biobank, BioVU at Vanderbilt and MyCode. These repositories were designed to generate information to enable a precision medicine approach to diagnose, prevent, and treat human disease.
- 1 October 2022
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 15 (5) , 356-358
Hidden Risk: Arrhythmogenic Genes in the General Population
The past 2 decades have seen the development of large-scale DNA biobanks associated with phenotypic information of the general population. Examples of these efforts are the UK Biobank, BioVU at Vanderbilt and MyCode. These repositories were designed to generate information to enable a precision medicine approach to diagnose, prevent, and treat human disease.
- 27 September 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (12) , 2988-2993
Consequences of treatment for hemophagocytic lymphohistiocytosis in a patient with undiagnosed Gaucher disease Type 1
Gaucher disease, a lysosomal storage disorder and hemophagocytic lymphohistiocytosis (HLH), a disorder of the immune system, have several overlapping clinical features including cytopenias, elevated serum ferritin, and splenomegaly. Prior reports of acute infantile neuronopathic, Type 2 Gaucher disease manifesting with signs of HLH have been published. Here we describe an adult patient who was initially suspected of having HLH, and was treated with a 10‐day course of etoposide and a 5‐day course alemtuzumab for presumptive HLH, only to later to have his presentation be determined to be due to Type 1 Gaucher disease. HLH chemotherapy treatment appeared to trigger a severe Gaucher acute pain crisis and extensive bony disease including avascular necrosis. Prolonged immunosuppression, and recurrent infections further complicated a lengthy hospitalization. We discuss the clinical overlap between Gaucher and HLH and the iatrogenic consequences of HLH‐directed therapy on underlying Type 1 Gaucher disease.
- 27 September 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (12) , 2988-2993
Consequences of treatment for hemophagocytic lymphohistiocytosis in a patient with undiagnosed Gaucher disease Type 1
Gaucher disease, a lysosomal storage disorder and hemophagocytic lymphohistiocytosis (HLH), a disorder of the immune system, have several overlapping clinical features including cytopenias, elevated serum ferritin, and splenomegaly. Prior reports of acute infantile neuronopathic, Type 2 Gaucher disease manifesting with signs of HLH have been published. Here we describe an adult patient who was initially suspected of having HLH, and was treated with a 10‐day course of etoposide and a 5‐day course alemtuzumab for presumptive HLH, only to later to have his presentation be determined to be due to Type 1 Gaucher disease. HLH chemotherapy treatment appeared to trigger a severe Gaucher acute pain crisis and extensive bony disease including avascular necrosis. Prolonged immunosuppression, and recurrent infections further complicated a lengthy hospitalization. We discuss the clinical overlap between Gaucher and HLH and the iatrogenic consequences of HLH‐directed therapy on underlying Type 1 Gaucher disease.
- 1 February 2020
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 139, 124-134
Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53
- 1 February 2020
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 139, 124-134
Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53
- Top Cited PapersOpen Access
- 12 November 2018
- Published by Springer Nature in BMC Genomics
- Vol. 19 (1) , 1-14
Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure
Current heart failure (HF) treatment is based on targeting symptoms and left ventricle dysfunction severity, relying on a common HF pathway paradigm to justify common treatments for HF patients. This common strategy may belie an incomplete understanding of heterogeneous underlying mechanisms and could be a barrier to more precise treatments. We hypothesized we could use RNA-sequencing (RNA-seq) in human heart tissue to delineate HF etiology-specific gene expression signatures. RNA-seq from 64 human left ventricular samples: 37 dilated (DCM), 13 ischemic (ICM), and 14 non-failing (NF). Using a multi-analytic approach including covariate adjustment for age and sex, differentially expressed genes (DEGs) were identified characterizing HF and disease-specific expression. Pathway analysis investigated enrichment for biologically relevant pathways and functions. DCM vs NF and ICM vs NF had shared HF-DEGs that were enriched for the fetal gene program and mitochondrial dysfunction. DCM-specific DEGs were enriched for cell-cell and cell-matrix adhesion pathways. ICM-specific DEGs were enriched for cytoskeletal and immune pathway activation. Using the ICM and DCM DEG signatures from our data we were able to correctly classify the phenotypes of 24/31 ICM and 32/36 DCM samples from publicly available replication datasets. Our results demonstrate the commonality of mitochondrial dysfunction in end-stage HF but more importantly reveal key etiology-specific signatures. Dysfunctional cell-cell and cell-matrix adhesion signatures typified DCM whereas signals related to immune and fibrotic responses were seen in ICM. These findings suggest that transcriptome signatures may distinguish end-stage heart failure, shedding light on underlying biological differences between ICM and DCM.
- 12 November 2018
- Published by Springer Nature in BMC Genomics
- Vol. 19 (1) , 1-14
Top Cited PapersOpen AccessTranscriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure
Current heart failure (HF) treatment is based on targeting symptoms and left ventricle dysfunction severity, relying on a common HF pathway paradigm to justify common treatments for HF patients. This common strategy may belie an incomplete understanding of heterogeneous underlying mechanisms and could be a barrier to more precise treatments. We hypothesized we could use RNA-sequencing (RNA-seq) in human heart tissue to delineate HF etiology-specific gene expression signatures. RNA-seq from 64 human left ventricular samples: 37 dilated (DCM), 13 ischemic (ICM), and 14 non-failing (NF). Using a multi-analytic approach including covariate adjustment for age and sex, differentially expressed genes (DEGs) were identified characterizing HF and disease-specific expression. Pathway analysis investigated enrichment for biologically relevant pathways and functions. DCM vs NF and ICM vs NF had shared HF-DEGs that were enriched for the fetal gene program and mitochondrial dysfunction. DCM-specific DEGs were enriched for cell-cell and cell-matrix adhesion pathways. ICM-specific DEGs were enriched for cytoskeletal and immune pathway activation. Using the ICM and DCM DEG signatures from our data we were able to correctly classify the phenotypes of 24/31 ICM and 32/36 DCM samples from publicly available replication datasets. Our results demonstrate the commonality of mitochondrial dysfunction in end-stage HF but more importantly reveal key etiology-specific signatures. Dysfunctional cell-cell and cell-matrix adhesion signatures typified DCM whereas signals related to immune and fibrotic responses were seen in ICM. These findings suggest that transcriptome signatures may distinguish end-stage heart failure, shedding light on underlying biological differences between ICM and DCM.
- 21 September 2018
- Published by Wiley in Academic Emergency Medicine
- Vol. 26 (6) , 639-647
The Emergency Medicine Specimen Bank: An Innovative Approach To Biobanking In Acute Care
The Emergency Medicine Specimen Bank (EMSB) was developed to facilitate precision medicine in acute care. The EMSB is a biorepository of clinical health data and biospecimens collected from all adult English‐ or Spanish‐speaking individuals who are able and willing to provide consent and are treated at the UCHealth–University of Colorado Hospital Emergency Department. The EMSB is the first acute care biobank that seeks to enroll all patients, with all conditions who present to the ED. Acute care biobanking presents many challenges that are unique to acute care settings such as providing informed consent in a uniquely stressful and fast‐paced environment and collecting, processing, and storing samples for tens of thousands of patients per year. Here, we describe the process by which the EMSB overcame these challenges and was integrated into clinical workflow allowing for operation 24 hours a day, 7 days a week at a reasonable cost. Other institutions can implement this template, further increasing the power of biobanking research to inform treatment strategies and interventions for common and uncommon phenotypes in acute care settings.
- 21 September 2018
- Published by Wiley in Academic Emergency Medicine
- Vol. 26 (6) , 639-647
The Emergency Medicine Specimen Bank: An Innovative Approach To Biobanking In Acute Care
The Emergency Medicine Specimen Bank (EMSB) was developed to facilitate precision medicine in acute care. The EMSB is a biorepository of clinical health data and biospecimens collected from all adult English‐ or Spanish‐speaking individuals who are able and willing to provide consent and are treated at the UCHealth–University of Colorado Hospital Emergency Department. The EMSB is the first acute care biobank that seeks to enroll all patients, with all conditions who present to the ED. Acute care biobanking presents many challenges that are unique to acute care settings such as providing informed consent in a uniquely stressful and fast‐paced environment and collecting, processing, and storing samples for tens of thousands of patients per year. Here, we describe the process by which the EMSB overcame these challenges and was integrated into clinical workflow allowing for operation 24 hours a day, 7 days a week at a reasonable cost. Other institutions can implement this template, further increasing the power of biobanking research to inform treatment strategies and interventions for common and uncommon phenotypes in acute care settings.
- 1 April 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (2) , 215-224
Genetic Infiltrative Cardiomyopathies
- 1 April 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (2) , 215-224
Genetic Infiltrative Cardiomyopathies
- Open Access
- 1 April 2018
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 4 (4) , 504-514
Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell–Cell Adhesion Structures
- 1 April 2018
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 4 (4) , 504-514
Open AccessFilamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell–Cell Adhesion Structures
- 1 July 2017
- Published by Edizioni Minerva Medica in International Angiology
- Vol. 36 (5) , 417-+
Clinical and genetic characterization of adult patients presenting with non-syndromic vascular aneurysms and dissections
Article: Clinical and genetic characterization of adult patients presenting with non-syndromic vascular aneurysms and dissections - International Angiology 2017 October;36(5):417-27 - Minerva Medica - Journals
- 1 July 2017
- Published by Edizioni Minerva Medica in International Angiology
- Vol. 36 (5) , 417-+
Clinical and genetic characterization of adult patients presenting with non-syndromic vascular aneurysms and dissections
Article: Clinical and genetic characterization of adult patients presenting with non-syndromic vascular aneurysms and dissections - International Angiology 2017 October;36(5):417-27 - Minerva Medica - Journals